KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab

British Journal of Surgery

Volumn 99, Issue 11, 2012, Pages 1575-1582

  Stremitzer, S ^a   Stift, J ^a   Gruenberger, B ^a   Tamandl, D ^a   Aschacher, T ^a   Wolf, B ^a   Wrba, F ^a   Gruenberger, T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; B RAF KINASE; BEVACIZUMAB; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ARTICLE; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PROSPECTIVE STUDY; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84867085917     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8909     Document Type: Article

References (34)

1. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
2. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al., Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
3. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al.,; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al., Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
6. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-696.
7. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
8. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang, Chien CR, Makhson A, et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
9. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
10. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al., American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
11. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, et al., Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000; 60: 490-498.
12. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA,. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-231.
13. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB,. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 1996; 16: 3839-3844.
14. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J,. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993; 104: 1044-1048.
15. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ,. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59: 747-751.
16. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al., Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993; 104: 57-64.
17. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al., Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102: 1136-1141.
18. Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, et al., Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002; 75: 903-908.
19. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al., Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
20. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
21. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
22. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M,. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554-4560.
23. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, et al.,; European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985-992.
24. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al., A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048.
25. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T,. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008; 8: 120.
26. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al., Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061.
27. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al., Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-989.
28. Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A, ten Kate J,. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994; 54: 3376-3378.
29. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, et al., KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17: 572-578.
30. Markowitz S, Hines JD, Lutterbaugh J, Myeroff L, Mackay W, Gordon N, et al., Mutant K-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival. Clin Cancer Res 1995; 1: 441-445.
31. Clarke GA, Ryan E, Crowe JP, O'Keane JC, MacMathuna P,. Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int J Colorectal Dis 2001; 16: 108-111.
32. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, et al., Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001; 27: 80-87.
33. Kastrinakis WV, Ramchurren N, Maggard M, Steele G Jr, Summerhayes IC,. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995; 130: 9-14.
34. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al., KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.